{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:38:58Z","timestamp":1793770738600,"version":"4.6.1"},"reference-count":235,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2019-I2M-5-004"],"award-info":[{"award-number":["2019-I2M-5-004"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902784"],"award-info":[{"award-number":["81902784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2022YFSY0058"],"award-info":[{"award-number":["2022YFSY0058"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ctrv.2024.102828","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T03:25:39Z","timestamp":1725679539000},"page":"102828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Bone complications of cancer treatment"],"prefix":"10.1016","volume":"130","author":[{"given":"Nanxi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Qiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102828_b0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2013revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2024.102828_b0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/oral3010011","article-title":"Oral toxicities in cancer patients, who receive immunotherapy: a case series of 24 patients","volume":"3","author":"Nicolatou-Galitis","year":"2023","journal-title":"Oral"},{"key":"10.1016\/j.ctrv.2024.102828_b0020","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2024.102828_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","article-title":"Disorders of bone remodeling","volume":"6","author":"Feng","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ctrv.2024.102828_b0030","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102828_b0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41574-019-0246-y","article-title":"The role of osteoblasts in energy homeostasis","volume":"15","author":"Dirckx","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ctrv.2024.102828_b0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2024.102828_b0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ctrv.2024.102828_b0050","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.5435\/JAAOS-D-18-00491","article-title":"Musculoskeletal effects of cancer and cancer treatment","volume":"28","author":"Wustrack","year":"2020","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0055","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2020.12.043","article-title":"Osteoradionecrosis: Exposing the Evidence Not the Bone","volume":"109","author":"Frankart","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10006-009-0198-9","article-title":"Osteoradionecrosis of the jaws\u2013a current overview\u2013part 1: Physiopathology and risk and predisposing factors","volume":"14","author":"Chrcanovic","year":"2010","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.amjoto.2018.12.006","article-title":"Osteoradionecrosis of the hyoid bone complicated by pharyngocutaneous fistula: A case report and literature review","volume":"40","author":"Sharif","year":"2019","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ctrv.2024.102828_b0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/MAO.0000000000000321","article-title":"Osteoradionecrosis of the temporal bone: a case series","volume":"35","author":"Sharon","year":"2014","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.ctrv.2024.102828_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3171\/spi.2005.3.2.0159","article-title":"Osteoradionecrosis of the cervical spine resulting from radiotherapy for primary head and neck malignancies: operative and nonoperative management","volume":"3","author":"Donovan","year":"2005","journal-title":"Case report J Neurosurg Spine"},{"key":"10.1016\/j.ctrv.2024.102828_b0080","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1177\/0003489419865558","article-title":"Anterior Skull Base Reconstruction following Ablative Surgery for Osteoradionecrosis: Case Report and Review of Literature","volume":"128","author":"Chapchay","year":"2019","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.ctrv.2024.102828_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010604.pub2","article-title":"Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults","author":"van den Blink","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2024.102828_b0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/idj.12318","article-title":"Osteoradionecrosis of the jaws: definition, epidemiology, staging and clinical and radiological findings. A concise review","volume":"68","author":"Chronopoulos","year":"2018","journal-title":"Int Dent J"},{"key":"10.1016\/j.ctrv.2024.102828_b0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00000421-200204000-00013","article-title":"Osteoradionecrosis of the mandible: scientific basis for clinical staging","volume":"25","author":"Schwartz","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hed.10171","article-title":"Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy","volume":"25","author":"Notani","year":"2003","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2024.102828_b0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/hed.2880140406","article-title":"Bone and gallium scans in postradiotherapy osteonecrosis of the jaw","volume":"14","author":"Epstein","year":"1992","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2024.102828_b0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tripleo.2009.10.001","article-title":"Radiation effects on bone healing and reconstruction: interpretation of the literature","volume":"109","author":"Jegoux","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.ctrv.2024.102828_b0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11914-013-0174-z","article-title":"Effects of radiation on bone","volume":"11","author":"Pacheco","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.ctrv.2024.102828_b0120","first-page":"21","article-title":"The influence of radiation on bone and bone cells-differential effects on osteoclasts and osteoblasts","author":"Donaubauer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102828_b0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1083\/jcb.201010010","article-title":"Type XII collagen regulates osteoblast polarity and communication during bone formation","volume":"193","author":"Izu","year":"2011","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ctrv.2024.102828_b0130","first-page":"12","article-title":"Bench to bedside: animal models of radiation induced musculoskeletal toxicity","author":"Farris","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102828_b0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/03008207.2017.1290085","article-title":"Osteoblast-osteoclast interactions","volume":"59","author":"Chen","year":"2018","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2021.02.007","article-title":"Mechanisms of radiation-induced endothelium damage: Emerging models and technologies","volume":"158","author":"Wijerathne","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0145","first-page":"398","article-title":"Regeneration of locally irradiated bone marrow. I. Dose dependent, long-term changes in the rat, with particular emphasis upon vascular and stromal reaction","volume":"28","author":"Knospe","year":"1966","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102828_b0150","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V73.6.1677.1677","article-title":"Hematopoietic bone marrow recovery after radiation therapy: MRI evaluation","volume":"73","author":"Casamassima","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102828_b0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2014.02.018","article-title":"Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors","volume":"63","author":"Green","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2024.102828_b0160","first-page":"17","article-title":"Infectious diseases of the jaws","volume":"28","author":"Meyer","year":"1970","journal-title":"J Oral Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0278-2391(83)80005-6","article-title":"A new concept in the treatment of osteoradionecrosis","volume":"41","author":"Marx","year":"1983","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.radonc.2004.08.021","article-title":"The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway","volume":"73","author":"Delanian","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0175","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2008.12.052","article-title":"Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients","volume":"75","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b0180","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/1097-0142(197606)37:6<2580::AID-CNCR2820370603>3.0.CO;2-H","article-title":"The treatment of radiation necrosis with hyperbaric oxygen (OHP)","volume":"37","author":"Hart","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-020-01542-2","article-title":"The effect of hyperbaric oxygen therapy on bone macroscopy, composition and biomechanical properties after ionizing radiation injury","volume":"15","author":"J\u00fanior","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.coms.2011.04.011","article-title":"Osteoradionecrosis","volume":"23","author":"O'Dell","year":"2011","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2024.102828_b0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.otohns.2009.03.013","article-title":"Analysis of outcomes of vascularized flap reconstruction in patients with advanced mandibular osteoradionecrosis","volume":"141","author":"Alam","year":"2009","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102828_b0205","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coms.2015.06.003","article-title":"The frequency of medication-related osteonecrosis of the jaw and its associated risk factors","volume":"27","author":"Dodson","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2024.102828_b0215","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2024.102828_b0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","article-title":"Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials","volume":"158","author":"Van Acker","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2024.102828_b0230","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djz215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2019","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"10.1016\/j.ctrv.2024.102828_b0235","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11914-020-00621-3","article-title":"Do bisphosphonates alleviate pain in children? a systematic review","volume":"18","author":"Celin","year":"2020","journal-title":"Curr Osteoporosis Rep"},{"key":"10.1016\/j.ctrv.2024.102828_b0240","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102828_b0245","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S0022215118000324","article-title":"Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature","volume":"132","author":"McCadden","year":"2018","journal-title":"J Laryngol Otol"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2024.102828_b0250","first-page":"S175","article-title":"Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review","volume":"120","author":"Phillips","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ctrv.2024.102828_b0255","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.amjoto.2016.05.002","article-title":"Bisphosphonate related osteonecrosis of calvarial bone","volume":"37","author":"Prueter","year":"2016","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ctrv.2024.102828_b0260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijom.2011.12.016","article-title":"Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease","volume":"41","author":"Marx","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/odi.12632","article-title":"Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study","volume":"23","author":"Fung","year":"2017","journal-title":"Oral Dis"},{"key":"10.1016\/j.ctrv.2024.102828_b0270","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.2010.05768.x","article-title":"Bisphosphonate-related osteonecrosis of the jaw: an overview","volume":"1218","author":"Ruggiero","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2024.102828_b0275","doi-asserted-by":"crossref","unstructured":"Lorenzo-Pouso AI, Bag\u00e1n J, Bag\u00e1n L, G\u00e1ndara-Vila P, Chamorro-Petronacci CM, Castelo-Baz P, et al. Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review. J Clin Med. 2021;10.doi: 10.3390\/jcm10194367.","DOI":"10.3390\/jcm10194367"},{"key":"10.1016\/j.ctrv.2024.102828_b0280","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jcms.2021.02.018","article-title":"Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis","volume":"49","author":"Schoenhof","year":"2021","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0285","first-page":"177","article-title":"The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and\/or bevacizumab","volume":"28","author":"Papadopoulou","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0290","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0295","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-13-0042","article-title":"IL-17-mediated M1\/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0300","first-page":"364","article-title":"Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw","volume":"3","author":"Marini","year":"2011","journal-title":"Front Biosci (Elite Ed)"},{"key":"10.1016\/j.ctrv.2024.102828_b0305","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102828_b0310","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00784-018-2655-z","article-title":"Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw","volume":"23","author":"Zirk","year":"2019","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.ctrv.2024.102828_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.644986","article-title":"Membrane Transport Proteins in Osteoclasts: The Ins and Outs","volume":"9","author":"Ribet","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ctrv.2024.102828_b0320","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.joms.2010.07.017","article-title":"Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism","volume":"68","author":"Otto","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0325","doi-asserted-by":"crossref","unstructured":"Jabbour Z, do Nascimento C, El-Hakim M, Henderson JE, de Albuquerque Junior RF. Bacterial profile and bone healing in rats receiving cancer therapeutic doses of bisphosphonates and corticosteroids: a pilot study. Int J Oral Maxillofac Surg. 2016;45:1162-9.doi: 10.1016\/j.ijom.2015.12.017.","DOI":"10.1016\/j.ijom.2015.12.017"},{"key":"10.1016\/j.ctrv.2024.102828_b0330","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0335","first-page":"5","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: a challenge, a responsibility, and an opportunity","volume":"28","author":"Marx","year":"2008","journal-title":"Int J Periodontics Restorative Dent"},{"key":"10.1016\/j.ctrv.2024.102828_b0340","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0345","doi-asserted-by":"crossref","unstructured":"Rollason V, Laverri\u00e8re A, MacDonald LC, Walsh T, Tram\u00e8r MR, Vogt-Ferrier NB. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev. 2016;2:Cd008455.doi: 10.1002\/14651858.CD008455.pub2.","DOI":"10.1002\/14651858.CD008455.pub2"},{"key":"10.1016\/j.ctrv.2024.102828_b0350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cden.2013.12.006","article-title":"Antiresorptive drug-related osteonecrosis of the jaw","volume":"58","author":"Uyanne","year":"2014","journal-title":"Dent Clin North Am"},{"key":"10.1016\/j.ctrv.2024.102828_b0355","unstructured":"Goker F, Grecchi E, Grecchi F, Francetti L, Del Fabbro M. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci. 2021;25:2662-73.doi: 10.26355\/eurrev_202103_25430."},{"key":"10.1016\/j.ctrv.2024.102828_b0360","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0365","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: Different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2024.102828_b0370","doi-asserted-by":"crossref","unstructured":"Zheng GZ, Chang B, Lin FX, Xie D, Hu QX, Yu GY, et al. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. Eur J Cancer Care (Engl). 2017;26.doi: 10.1111\/ecc.12541.","DOI":"10.1111\/ecc.12541"},{"key":"10.1016\/j.ctrv.2024.102828_b0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2024.102828_b0380","doi-asserted-by":"crossref","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25:e326-e36.doi: 10.4317\/medoral.23324.","DOI":"10.4317\/medoral.23324"},{"key":"10.1016\/j.ctrv.2024.102828_b0385","first-page":"4763","article-title":"Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases","volume":"29","author":"Ikesue","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0390","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00774-021-01223-4","article-title":"Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis","volume":"39","author":"Aoki","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.ctrv.2024.102828_b0395","first-page":"2811","article-title":"Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review","volume":"29","author":"Querrer","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0400","doi-asserted-by":"crossref","unstructured":"Okuma S, Matsuda Y, Nariai Y, Karino M, Suzuki R, Kanno T. A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers. Cancers (Basel). 2020;12.doi: 10.3390\/cancers12051209.","DOI":"10.3390\/cancers12051209"},{"key":"10.1016\/j.ctrv.2024.102828_b0405","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcms.2017.01.013","article-title":"Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ)","volume":"45","author":"Hoefert","year":"2017","journal-title":"J Cranio-Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0410","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00198-021-05995-3","article-title":"Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study","volume":"32","author":"Hasegawa","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2024.102828_b0415","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/jop.12646","article-title":"Denosumab-related osteonecrosis of the jaw: A retrospective study","volume":"47","author":"Egloff-Juras","year":"2018","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.ctrv.2024.102828_b0420","doi-asserted-by":"crossref","unstructured":"Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol. 2021;87:871-7.doi: 10.1007\/s00280-021-04262-w.","DOI":"10.1007\/s00280-021-04262-w"},{"key":"10.1016\/j.ctrv.2024.102828_b0425","doi-asserted-by":"crossref","unstructured":"Boquete-Castro A, G\u00f3mez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016;27:367-75.doi: 10.1111\/clr.12556.","DOI":"10.1111\/clr.12556"},{"key":"10.1016\/j.ctrv.2024.102828_b0430","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.joms.2020.11.017","article-title":"Comparing the Surgical Response of Bisphosphonate-Related Versus Denosumab-Related Osteonecrosis of the Jaws","volume":"79","author":"Palla","year":"2021","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0435","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcms.2018.05.046","article-title":"Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series","volume":"46","author":"Aljohani","year":"2018","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0440","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102828_b0445","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.coms.2015.06.004","article-title":"The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw","volume":"27","author":"Fantasia","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2024.102828_b0450","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102828_b0455","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0460","doi-asserted-by":"crossref","unstructured":"Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Rom\u00e1n-Gil M, Orejana-Mart\u00edn I, Torres-Jim\u00e9nez J, et al. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci. 2020;21.doi: 10.3390\/ijms21228529.","DOI":"10.3390\/ijms21228529"},{"key":"10.1016\/j.ctrv.2024.102828_b0465","doi-asserted-by":"crossref","unstructured":"Tian T, Li X, Zhang J. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int J Mol Sci. 2019;20.doi: 10.3390\/ijms20030755.","DOI":"10.3390\/ijms20030755"},{"key":"10.1016\/j.ctrv.2024.102828_b0470","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.ctrv.2024.102828_b0475","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Hamadeh","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102828_b0480","first-page":"869","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"van Cann","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0485","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon.13.211","article-title":"Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents","volume":"10","author":"Campisi","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102828_b0495","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and Managing Toxicities of High-Dose Methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102828_b0500","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.joms.2017.05.027","article-title":"Methotrexate-Related Lymphoproliferative Disorder in Patients With Osteonecrosis of the Jaw: A 3-Case Report and Literature Review","volume":"76","author":"Furudate","year":"2018","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0505","article-title":"Promising applications of steroid conjugates for cancer research and treatment","volume":"210","author":"Az","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ctrv.2024.102828_b0510","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102828_b0515","doi-asserted-by":"crossref","DOI":"10.3389\/froh.2022.968157","article-title":"Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider","volume":"3","author":"Klein","year":"2022","journal-title":"Front Oral Health"},{"key":"10.1016\/j.ctrv.2024.102828_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102460","article-title":"The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis","volume":"110","author":"Chang","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ctrv.2024.102828_b0525","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2018.05.091","article-title":"The pathogenesis of steroid-induced osteonecrosis of the femoral head: A systematic review of the literature","volume":"671","author":"Wang","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.ctrv.2024.102828_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119828","article-title":"Magnesium and vitamin C supplementation attenuates steroid-associated osteonecrosis in a rat model","volume":"238","author":"Zheng","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.ctrv.2024.102828_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-023-04482-z","article-title":"Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention","volume":"21","author":"Li","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2024.102828_b0540","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.oraloncology.2015.08.014","article-title":"Osteonecrosis of the jaw a new complication related to Ipilimumab","volume":"51","author":"Owosho","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0545","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/imt-2020-0108","article-title":"Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report","volume":"12","author":"Pundole","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2024.102828_b0550","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jormas.2020.05.001","article-title":"Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab","volume":"121","author":"Decaux","year":"2020","journal-title":"J Stomatol, Oral Maxillofacial Surg"},{"key":"10.1016\/j.ctrv.2024.102828_b0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0560","article-title":"The role of the immune response in the development of medication-related osteonecrosis of the jaw","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102828_b0565","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/labinvest.2012.89","article-title":"The suppression of TRIM21 and the accumulation of IFN-\u03b1 play crucial roles in the pathogenesis of osteonecrosis of the femoral head","volume":"92","author":"Tateda","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.ctrv.2024.102828_b0570","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2024.102828_b0575","doi-asserted-by":"crossref","unstructured":"Vasconcelos de Matos L, Fernandes L, Neves MT, Alves F, Baleiras M, Ferreira A, et al. From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors. Current oncology (Toronto, Ont). 2021;28:1067\u201376.doi: 10.3390\/curroncol28020104.","DOI":"10.3390\/curroncol28020104"},{"key":"10.1016\/j.ctrv.2024.102828_b0580","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102828_b0585","doi-asserted-by":"crossref","unstructured":"Nisha Y, Dubashi B, Bobby Z, Sahoo JP, Kayal S. Effect of cytotoxic chemotherapy on bone health among breast cancer patients. Does it require intervention? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2021;29:6957\u201372.doi: 10.1007\/s00520-021-06231-8.","DOI":"10.1007\/s00520-021-06231-8"},{"key":"10.1016\/j.ctrv.2024.102828_b0590","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-017-4308-3","article-title":"Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model","volume":"165","author":"Fan","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2024.102828_b0595","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jbmr.2415","article-title":"Myelosuppressive Therapies Significantly Increase ProInflammatory Cytokines and Directly Cause Bone Loss","volume":"30","author":"Quach","year":"2015","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0600","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2905-x","article-title":"Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients","volume":"16","author":"Monroy-Cisneros","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0605","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0019-509X.55554","article-title":"Cancer chemotherapy-induced osteoporosis: How common is it among Saudi Arabian cancer survivors","volume":"46","author":"Al Amri","year":"2009","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0610","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102658","article-title":"Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases","volume":"19","author":"Szekanecz","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ctrv.2024.102828_b0620","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00198-019-05103-6","article-title":"Bone health in estrogen-free contraception","volume":"30","author":"Hadji","year":"2019","journal-title":"Osteoporosis Int : A J Established Result Cooperation Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"10.1016\/j.ctrv.2024.102828_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2022.151280","article-title":"Direct and indirect mechanisms of chemotherapy-induced bone loss in adjuvant breast cancer: an integrative review","volume":"38","author":"Rayner-Myers","year":"2022","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ctrv.2024.102828_b0630","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/0008-5472.CAN-19-2348","article-title":"Therapy-Induced Senescence Drives Bone Loss","volume":"80","author":"Yao","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0635","first-page":"E392","article-title":"Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone","volume":"34","author":"Ponnapakkam","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ctrv.2024.102828_b0640","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00774-015-0679-x","article-title":"Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats","volume":"34","author":"Fan","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.ctrv.2024.102828_b0645","first-page":"180","article-title":"Chemo\/radiotherapy-Induced Bone Marrow Niche Alterations","volume":"39","author":"Rafieemehr","year":"2021","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2024.102828_b0650","article-title":"Methotrexate treatment suppresses osteoblastic differentiation by inducing Notch2 signaling and blockade of Notch2 rescues osteogenesis by preserving Wnt\/\u03b2-catenin signaling","author":"Peymanfar","year":"2021","journal-title":"J Orthop Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0655","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2004.04.199","article-title":"Skeletal morbidity in childhood acute lymphoblastic leukemia","volume":"22","author":"Mandel","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0660","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.13.5517","article-title":"Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0665","doi-asserted-by":"crossref","first-page":"22486","DOI":"10.1038\/s41598-021-01140-6","article-title":"Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102828_b0670","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0675","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fonc.2020.01125","article-title":"Bone fracture incidence after androgen deprivation therapy-investigational agents: results from cancer therapy evaluation program-sponsored early phase clinical trials 2006\u20132013","volume":"10","author":"Myint","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0680","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","article-title":"Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer","volume":"30","author":"Yu","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0685","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1200\/jco.2007.25.18_suppl.5116","article-title":"Prevalence of osteoporosis and osteopenia during androgen deprivation (ADT) for prostate cancer: Baseline data from a large randomized controlled trial","volume":"25","author":"Malkowicz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0690","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrendo.2009.112","article-title":"Estrogens as regulators of bone health in men","volume":"5","author":"Vandenput","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ctrv.2024.102828_b0695","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00198-018-4793-1","article-title":"Vertebral fractures cascade: potential causes and risk factors","volume":"30","author":"Che","year":"2019","journal-title":"Osteoporosis Int : A J Established Result Cooperation Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"10.1016\/j.ctrv.2024.102828_b0700","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5694\/mja2.50280","article-title":"Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary","volume":"211","author":"Grossmann","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.ctrv.2024.102828_b0705","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0710","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Williams","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0715","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0720","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2012.42.2097","article-title":"Bone Health in Adult Cancer Survivorship","volume":"30","author":"Lustberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0725","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V58.6.1198.1198","article-title":"The effects of glucocorticoid therapy on glucocorticoid receptors in leukemia and lymphoma","volume":"58","author":"Shipman","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102828_b0730","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ctrv.2024.102828_b0735","first-page":"22","article-title":"Glucocorticoid receptor regulates TNFSF11 transcription by binding to glucocorticoid responsive element in TNFSF11 proximal promoter region","author":"Lov\u0161in","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102828_b0740","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/tcmj.tcmj_233_20","article-title":"The molecular etiology and treatment of glucocorticoid-induced osteoporosis","volume":"33","author":"Peng","year":"2021","journal-title":"Tzu chi Med J"},{"key":"10.1016\/j.ctrv.2024.102828_b0745","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/aps.2017.134","article-title":"Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15\/PPAR gamma 2 signaling in GIO rats","volume":"39","author":"Yang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ctrv.2024.102828_b0750","first-page":"8","article-title":"Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo","author":"Hildebrandt","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102828_b0755","doi-asserted-by":"crossref","first-page":"E597","DOI":"10.1152\/ajpendo.00292.2017","article-title":"WNT16 overexpression partly protects against glucocorticoid-induced bone loss","volume":"314","author":"Ohlsson","year":"2018","journal-title":"Am J Physiol-Endocrinol Metabol"},{"key":"10.1016\/j.ctrv.2024.102828_b0760","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/jbmr.3407","article-title":"J-Shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective Cohort study","volume":"33","author":"Shin","year":"2018","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0765","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102828_b0770","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.surg.2011.09.013","article-title":"Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study","volume":"150","author":"Sugitani","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2024.102828_b0775","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0163-7258(83)90073-6","article-title":"Drug and hormone effects on calcium release from bone","volume":"21","author":"Martin","year":"1983","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2024.102828_b0780","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodeling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102828_b0785","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1172\/JCI63948","article-title":"Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling","volume":"122","author":"Baliram","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2024.102828_b0790","first-page":"21","article-title":"Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects","author":"Tenti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102828_b0795","first-page":"12","article-title":"The association of vitamin D status with lipid profile and inflammation biomarkers in healthy adolescents","author":"Yarparvar","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ctrv.2024.102828_b0800","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, Calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US preventive services task force","volume":"319","author":"Kahwati","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2024.102828_b0805","first-page":"347","article-title":"The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials","author":"El-Khoury","year":"2013","journal-title":"BMJ-Brit Med J"},{"key":"10.1016\/j.ctrv.2024.102828_b0810","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0815","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","article-title":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","volume":"86","author":"Briot","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ctrv.2024.102828_b0820","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14712598.2020.1814731","article-title":"Denosumab for cancer-related bone loss","volume":"20","author":"Dell'Aquila","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2024.102828_b0825","first-page":"195","article-title":"Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study","volume":"13","author":"Doria","year":"2016","journal-title":"Clin Cases Miner Bone Metabol : Off J Italian Soc Osteoporosis, Mineral Metabol, Skeletal Dis"},{"key":"10.1016\/j.ctrv.2024.102828_b0830","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40266-020-00748-z","article-title":"The evolving complexity of treating hormone receptor-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer: special considerations in older breast cancer patients-part I: early-stage disease","volume":"37","author":"Sammons","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ctrv.2024.102828_b0835","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102828_b0840","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jbmr.3886","article-title":"Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates","volume":"35","author":"Pineda-Moncusi","year":"2020","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.ctrv.2024.102828_b0845","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102828_b0850","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0855","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0865","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0870","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14740338.2021.1861246","article-title":"The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn","volume":"20","author":"Deligiorgi","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ctrv.2024.102828_b0875","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2016.71.6902","article-title":"Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy","volume":"35","author":"Teepen","year":"2017","journal-title":"J Clin Oncol : Off J Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0880","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2013.54.7844","article-title":"Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy","volume":"32","author":"Wong","year":"2014","journal-title":"J Clin Oncol : Off J Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0885","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<370::AID-IJC11>3.0.CO;2-C","article-title":"Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood","volume":"77","author":"Le Vu","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0890","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.26193","article-title":"Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center","volume":"64","author":"Temming","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0895","doi-asserted-by":"crossref","unstructured":"Khanna L, Prasad SR, Yedururi S, Parameswaran AM, Marcal LP, Sandrasegaran K, et al. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings. Radiographics : a review publication of the Radiological Society of North America, Inc. 2021;41:876\u201394.doi: 10.1148\/rg.2021200171.","DOI":"10.1148\/rg.2021200171"},{"key":"10.1016\/j.ctrv.2024.102828_b0900","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-W","article-title":"Sarcoma arising in irradiated bone - Report of eleven cases","volume":"82","author":"Cahan","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0905","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(99)00279-5","article-title":"Postradiation sarcomas: 20 cases and a literature review","volume":"45","author":"Murray","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b0910","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.ejso.2019.04.010","article-title":"Osteosarcoma after the age of fifty: A clinicopathological study","volume":"45","author":"Tempelaere","year":"2019","journal-title":"Eur J Surg Oncol : J Eur Soc Surg Oncol Brit Associat Surg Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0915","doi-asserted-by":"crossref","unstructured":"Yamanaka R, Hayano A. Secondary craniofacial sarcomas following retinoblastoma: a systematic review. World neurosurgery. 2017;101:722-30.e4.doi: 10.1016\/j.wneu.2017.02.031.","DOI":"10.1016\/j.wneu.2017.02.031"},{"key":"10.1016\/j.ctrv.2024.102828_b0920","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/MPH.0000000000001442","article-title":"Development of Secondary Osteosarcoma After TBI and Allogeneic Bone Marrow Transplant: A Case Series of 3 Patients","volume":"42","author":"Scheuermann","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b0925","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/pbc.26067","article-title":"Osteosarcoma after hematopoietic stem cell transplantation in children and adolescents: case report and review of the literature","volume":"63","author":"Kebudi","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b0930","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00264-019-04332-y","article-title":"Survival analysis of elderly patients with osteosarcoma","volume":"43","author":"Imura","year":"2019","journal-title":"Int Orthop"},{"key":"10.1016\/j.ctrv.2024.102828_b0935","doi-asserted-by":"crossref","unstructured":"Huvos AG, Woodard HQ, Cahan WG, Higinbotham NL, Stewart FW, Butler A, et al. Postradiation Osteogenic-Sarcoma of Bone and Soft-Tissues - A Clinicopathologic Study of 66 Patients. Cancer. 1985;55:1244\u201355.doi: 10.1002\/1097-0142(19850315)55:6<1244::Aid-cncr2820550617>3.0.Co;2-1.","DOI":"10.1002\/1097-0142(19850315)55:6<1244::AID-CNCR2820550617>3.0.CO;2-1"},{"key":"10.1016\/j.ctrv.2024.102828_b0940","first-page":"13","article-title":"At What age could screening for familial retinoblastoma be discontinued? a Systematic review","author":"Wijsard","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2024.102828_b0945","doi-asserted-by":"crossref","unstructured":"Vazquez E, Castellote A, Piqueras J, Ortuno P, Sanchez-Toledo J, Nogues P, et al. Second malignancies in pediatric patients: Imaging findings and differential diagnosis. Radiographics : a review publication of the Radiological Society of North America, Inc. 2003;23:1155\u201372.doi: 10.1148\/rg.235035040.","DOI":"10.1148\/rg.235035040"},{"key":"10.1016\/j.ctrv.2024.102828_b0950","first-page":"13","article-title":"Subsequent Malignant Neoplasms in Retinoblastoma Survivors","author":"Fabius","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2024.102828_b0955","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ophtha.2020.05.024","article-title":"Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma","volume":"127","author":"Tonorezos","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ctrv.2024.102828_b0960","doi-asserted-by":"crossref","unstructured":"Kleinerman RA, Schonfeld SJ, Sigel BS, Wong-Siegel JR, Gilbert ES, Abramson DH, et al. Bone and Soft\u2010Tissue Sarcoma Risk in Long\u2010Term Survivors of Hereditary Retinoblastoma Treated With Radiation. 2020.","DOI":"10.1200\/JCO.19.01096"},{"key":"10.1016\/j.ctrv.2024.102828_b0965","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jama.1997.03550150066037","article-title":"Cancer incidence after retinoblastoma - Radiation dose and sarcoma risk","volume":"278","author":"Wong","year":"1997","journal-title":"JAMA-J Am Med Associat"},{"key":"10.1016\/j.ctrv.2024.102828_b0970","first-page":"1","article-title":"Retinoblastoma","author":"Dimaras","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ctrv.2024.102828_b0975","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejmg.2018.07.017","article-title":"Correlation between RB1germline mutations and second primary malignancies in hereditary retinoblastoma patients treated with external beam radiotherapy","volume":"62","author":"Chaussade","year":"2019","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.ctrv.2024.102828_b0980","first-page":"110","article-title":"Risk of subsequent bone cancers among 69 460 five-year survivors of childhood and adolescent cancer in Europe","author":"Fidler","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102828_b0985","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1210\/er.2018-00092","article-title":"Long-term endocrine and metabolic consequences of cancer treatment: a systematic review","volume":"40","author":"Gebauer","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2024.102828_b0990","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13256-018-1606-2","article-title":"Radiation-induced chondrosarcoma of the scapula after radiotherapy for lung cancer: a case report and review of the literature","volume":"12","author":"Zidane","year":"2018","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.ctrv.2024.102828_b0995","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2603","article-title":"Radiation-induced bystander signalling in cancer therapy","volume":"9","author":"Prise","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b1000","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/carcin\/bgr064","article-title":"A transcriptome signature distinguished sporadic from postradiotherapy radiation-induced sarcomas","volume":"32","author":"Hadj-Hamou","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2024.102828_b1005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/pbc.24251","article-title":"Clinical features and outcomes in patients with secondary Ewing Sarcoma","volume":"60","author":"Applebaum","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b1010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/MPH.0000000000000721","article-title":"Ewing sarcoma of the bone with EWS\/FLI1 translocation after successful treatment of primary osteosarcoma","volume":"39","author":"Yodoya","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1015","doi-asserted-by":"crossref","first-page":"E609","DOI":"10.1097\/MPH.0000000000002282","article-title":"Ewing Sarcoma of the 9th Rib Subsequent to Pediatric Leukemia: A Case Series","volume":"44","author":"Vandenheuvel","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","article-title":"Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors","volume":"10","author":"Travis","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2011.11.022","article-title":"Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study","volume":"84","author":"Henderson","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b1030","doi-asserted-by":"crossref","unstructured":"Ren HY, Sun LL, Li HY, Ye ZM. Prognostic significance of serum alkaline phosphatase level in osteosarcoma: a meta-analysis of published data. BioMed Res Int. 2015;2015.doi: 10.1155\/2015\/160835.","DOI":"10.1155\/2015\/160835"},{"key":"10.1016\/j.ctrv.2024.102828_b1035","doi-asserted-by":"crossref","unstructured":"Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320-5.doi: 10.1093\/annonc\/mdq276.","DOI":"10.1093\/annonc\/mdq276"},{"key":"10.1016\/j.ctrv.2024.102828_b1040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/03009730903177340","article-title":"Secondary osteosarcoma arising after treatment for childhood hematologic malignancies","volume":"114","author":"Okada","year":"2009","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.ctrv.2024.102828_b1045","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.25734","article-title":"Radiation-Induced Osteosarcomas of the Calvarium and Skull Base","volume":"117","author":"Patel","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b1050","first-page":"1139","article-title":"Second primary osteosarcomas in patients with retinoblastoma","volume":"45","author":"Fujiwara","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1055","doi-asserted-by":"crossref","unstructured":"Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells. 2021;10.doi: 10.3390\/cells10010172.","DOI":"10.3390\/cells10010172"},{"key":"10.1016\/j.ctrv.2024.102828_b1060","doi-asserted-by":"crossref","unstructured":"Bree Rd, Moll AC, Imhof SM, Buter J, Leemans CR. Subsequent tumors in retinoblastoma survivors: The role of the head and neck surgeon. Oral Oncol. 2008;44:982\u20135.doi: 10.1016\/j.oraloncology.2007.12.005.","DOI":"10.1016\/j.oraloncology.2007.12.005"},{"key":"10.1016\/j.ctrv.2024.102828_b1065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MED.0b013e3283416441","article-title":"The accrual of bone mass during childhood and puberty","volume":"18","author":"Mughal","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ctrv.2024.102828_b1070","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ijrobp.2005.04.031","article-title":"Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant","volume":"63","author":"Faraci","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b1075","doi-asserted-by":"crossref","unstructured":"Eifel PJ, Donaldson SS, Thomas PRM. Response of growing bone to irradiation: A proposed late effects scoring system. Int J Radiat Oncology*Biology*Physics. 1995;31:1301-7.doi: https:\/\/doi.org\/10.1016\/0360-3016(94)00420-P.","DOI":"10.1016\/0360-3016(94)00420-P"},{"key":"10.1016\/j.ctrv.2024.102828_b1080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/0360-3016(81)90031-6","article-title":"Slipped femoral capital epiphyses in irradiated children: dose, volume and age relationships","volume":"7","author":"Silverman","year":"1981","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b1085","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S1368-8375(01)00002-1","article-title":"Disturbances in craniofacial morphology in children treated for solid tumors","volume":"37","author":"Karsila-Tenovuo","year":"2001","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1090","unstructured":"Board PDQPTE. Late Effects of Treatment for Childhood Cancer (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002."},{"key":"10.1016\/j.ctrv.2024.102828_b1095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1148\/114.1.155","article-title":"The Effects of Radiation Therapy on Bone Growth","volume":"114","author":"Probert","year":"1975","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2024.102828_b1100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2018.10.026","article-title":"A road map for important centers of growth in the pediatric skeleton to consider during radiation therapy and associated clinical correlates of radiation-induced growth toxicity","volume":"103","author":"Rao","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102828_b1105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.6065\/apem.2040060.030","article-title":"Low bone mineral density in children and adolescents with cancer","volume":"25","author":"Jin","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2024.102828_b1110","doi-asserted-by":"crossref","unstructured":"Siegel DA, Claridy M, Mertens A, George E, Vangile K, Simoneaux SF, et al. Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors. Pediatr Blood Cancer. 2017;64.doi: 10.1002\/pbc.26488.","DOI":"10.1002\/pbc.26488"},{"key":"10.1016\/j.ctrv.2024.102828_b1115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M","article-title":"Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission","volume":"25","author":"Ragab","year":"1970","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2024.102828_b1120","first-page":"80","article-title":"Effects of chemotherapy on bone metabolism and skeletal growth","volume":"58","author":"Siebler","year":"2002","journal-title":"Horm Res"},{"key":"10.1016\/j.ctrv.2024.102828_b1125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495943","article-title":"Hypogonadism in children with a previous history of cancer: endocrine management and follow-up","volume":"91","author":"van Santen","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.ctrv.2024.102828_b1130","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/bmj.298.6687.1560","article-title":"Hypophosphataemic rickets after ifosfamide treatment in children","volume":"298","author":"Skinner","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2024.102828_b1135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3747\/co.26.5033","article-title":"A general practitioner's guide to hematopoietic stem-cell transplantation","volume":"26","author":"Bazinet","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/cncr.22796","article-title":"Bone health in children and adolescents after allogeneic stem cell transplantation: high prevalence of vertebral compression fractures","volume":"110","author":"Taskinen","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b1145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2001.v7.pm11400947","article-title":"Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study","volume":"7","author":"Stern","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2024.102828_b1150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2024.102828_b1155","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000\u201307: population-based data from EUROCARE-5","volume":"17","author":"Trama","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1055-9965.EPI-14-1418","article-title":"Survivors of childhood cancer in the United States: prevalence and burden of morbidity","volume":"24","author":"Phillips","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2024.102828_b1165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/pbc.24445","article-title":"A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"60","author":"Kremer","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2024.102828_b1170","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1200\/JCO.2017.77.0180","article-title":"Surveillance for late effects in childhood cancer survivors","volume":"36","author":"Landier","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102828_b1175","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:22:15Z","timestamp":1777555335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":235,"alternative-id":["S0305737224001567"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102828","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone complications of cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102828"}}